Literature DB >> 10071197

P57 (KIP2) polymorphisms and breast cancer risk.

Y Li1, R C Millikan, B Newman, K Conway, C K Tse, E T Liu.   

Abstract

A previous report in this journal has suggested that germline deletions in the proline-alanine-rich (PAPA-repeat) region of P57 (KIP2) are associated with increased risk of a variety of cancers, including breast cancer. We have analyzed the association of P57 PAPA-repeat deletion polymorphisms and breast cancer risk as part of a population-based case-control study of breast cancer. We have not observed an association between the presence of one or two copies of deletion polymorphisms in P57 and breast cancer risk (adjusted odds ratio: 1.1, 95% confidence interval: 0.6-2.0). Further investigation is necessary to determine the functional significance of P57 deletion polymorphisms and their potential relationship with disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071197     DOI: 10.1007/s004390050914

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  2 in total

1.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence.

Authors:  A Tsugu; K Sakai; P B Dirks; S Jung; R Weksberg; Y L Fei; S Mondal; S Ivanchuk; C Ackerley; P A Hamel; J T Rutka
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

2.  Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.

Authors:  Ke-Jun Nan; Hui Guo; Zhi-Ping Ruan; Zhao Jing; Shaan-Xi Liu
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.